A new study published in Nature Medicine led by the National Cancer Center Hospital East in Japan, demonstrates that the Guardant360® liquid biopsy is not only concordant to tissue genotyping, but also accelerates clinical trial enrollment, detects more actionable alterations, and achieves similar treatment response rates and progression-free survival in patients with advanced gastrointestinal cancer.

Click on the press release link below to find out more: https://lnkd.in/dKxk2xB

Publication link: https://lnkd.in/g9hnGBf

Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at clientservices@guardantamea.com or contact us on WhatsApp: +65 8940 0360. Guardant360®. Test. Take Action.